Literature DB >> 2889958

Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease.

T W Meade1, J Imeson, Y Stirling.   

Abstract

The Northwick Park Heart Study (NPHS) has demonstrated associations of high levels of factor VII coagulant activity (VIIc) and of plasma fibrinogen concentration with the risk of subsequent ischaemic heart disease (IHD). In cross-sectional data from the 2023 white men in NPHS, lifetime duration of smoking was a determinant of initial plasma fibrinogen levels. Fibrinogen levels had apparently begun to fall soon after smoking was discontinued but it was over 5 years before they had returned to levels found in life-long non-smokers. In prospective data, smoking cessation and the adoption or resumption of smoking were associated with a decrease or an increase, respectively, of about 0.15 g/l in plasma fibrinogen. These changes would lower or raise the risk of IHD by about 20%. A switch from cigarettes to cigars was associated with a large increase in fibrinogen. A substantial part of the relation between smoking and IHD appears to be mediated through the fibrinogen concentration. Following changes in body mass, VIIc rose in those who had given up smoking and fell in those who resumed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2889958     DOI: 10.1016/s0140-6736(87)92556-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  40 in total

1.  Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors.

Authors:  E B Rimm; P Williams; K Fosher; M Criqui; M J Stampfer
Journal:  BMJ       Date:  1999-12-11

2.  The most cited authors and papers in tobacco control.

Authors:  F Byrne; S Chapman
Journal:  Tob Control       Date:  2005-06       Impact factor: 7.552

3.  Smoking, smoking cessation, and risk of cardiovascular disease.

Authors:  Peter W F Wilson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-08

4.  Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres.

Authors:  Mira Harrison-Woolrych; Linda Härmark; Ming Tan; Simran Maggo; Kees van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2012-02-08       Impact factor: 2.953

Review 5.  Drugs affecting plasma fibrinogen levels.

Authors:  G di Minno; M Mancini
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

6.  Fibrinogen and cardiovascular disease.

Authors:  T W Meade
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

7.  Potential biomechanical roles of risk factors in the evolution of thrombus-laden abdominal aortic aneurysms.

Authors:  Lana Virag; John S Wilson; Jay D Humphrey; Igor Karšaj
Journal:  Int J Numer Method Biomed Eng       Date:  2017-06-02       Impact factor: 2.747

8.  Ischaemic heart disease: association with haematocrit in the British Regional Heart Study.

Authors:  G Wannamethee; A G Shaper; P H Whincup
Journal:  J Epidemiol Community Health       Date:  1994-04       Impact factor: 3.710

Review 9.  Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.

Authors:  Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

10.  Racial differences in alcohol and tobacco use in adolescence and mid-adulthood in a community-based sample.

Authors:  John R Pamplin; Ezra S Susser; Pam Factor-Litvak; Bruce G Link; Katherine M Keyes
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-09-21       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.